TLSI TriSalus Life Sciences Inc revenue, earnings and financials
For the quarter ended June 30, 2026, TriSalus Life Sciences Inc reported revenue of $11.4M (up 1.7% from a year earlier), net income of −$9.19M and diluted EPS of −$0.16; over the last four quarters revenue was $45.1M and net income −$28.2M; for the fiscal year ended December 2025 revenue was $45.2M, up 53.4% on the year before.
TLSI annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $45.2M, gross profit $38.2M, operating income −$26.9M, net income −$39.2M (margin -86.9%), EPS −$1.84
- Fiscal year ended Dec 2024: revenue $29.4M, gross profit $25.3M, operating income −$36.2M, net income −$30.0M (margin -102.1%), EPS −$1.31
- Fiscal year ended Dec 2023: revenue $18.5M, gross profit $15.9M, operating income −$54.5M, net income −$59.4M (margin -320.7%), EPS −$6.77
- Fiscal year ended Dec 2022: revenue $12.4M, gross profit $10.1M, operating income −$36.4M, net income −$47.2M (margin -380.6%), EPS −$161.55
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$3.04M, net income $4.77M (margin n/a), EPS n/a
TLSI quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $11.4M (up 1.7% year over year), net income −$9.19M, EPS −$0.16
- Quarter ended Mar 31, 2026: revenue $8.90M (down 2.9% year over year), net income $1.54M, EPS $0.03
- Quarter ended Dec 31, 2025 (from the annual report): revenue $13.2M (up 59.8% year over year), net income −$9.75M, EPS −$0.22
- Quarter ended Sep 30, 2025: revenue $11.6M (up 57.4% year over year), net income −$10.8M, EPS −$0.96
- Quarter ended Jun 30, 2025: revenue $11.2M (up 52.3% year over year), net income −$8.29M, EPS −$0.27
- Quarter ended Mar 31, 2025: revenue $9.17M (up 42.0% year over year), net income −$10.4M, EPS −$0.39
- Quarter ended Dec 31, 2024 (from the annual report): revenue $8.26M (up 44.4% year over year), net income −$10.1M, EPS −$0.38
- Quarter ended Sep 30, 2024: revenue $7.35M (up 41.5% year over year), net income −$2.40M, EPS −$0.12
- Quarter ended Jun 30, 2024: revenue $7.36M (up 59.7% year over year), net income −$4.33M, EPS −$0.21
- Quarter ended Mar 31, 2024: revenue $6.46M (up 116.4% year over year), net income −$13.2M, EPS −$0.60
- Quarter ended Dec 31, 2023 (from the annual report): revenue $5.72M, net income −$35.6M, EPS $29.78
- Quarter ended Sep 30, 2023: revenue $5.19M (up 32.4% year over year), net income −$1.43M, EPS −$0.14
- Quarter ended Jun 30, 2023: revenue $4.61M, net income −$14.0M, EPS −$35.84
- Quarter ended Mar 31, 2023: revenue $2.98M, net income −$8.31M, EPS −$0.57
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$22.5M, EPS n/a
- Quarter ended Sep 30, 2022: revenue $3.92M, net income −$8.09M, EPS −$25.95
- Quarter ended Jun 30, 2022: revenue n/a, net income −$8.68M, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$7.87M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income $2.90M, EPS n/a
- Quarter ended Sep 30, 2021: revenue n/a, net income $1.86M, EPS n/a
TLSI cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$18.0M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$40.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$50.6M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$32.3M, share buybacks $232M
- Fiscal year ended Dec 2021: operating cash flow −$1.74M, share buybacks n/a
TLSI balance sheet
- Jun 30, 2026: cash $46.3M, total assets $62.4M, total liabilities $55.9M, shareholders' equity $6.55M, long-term debt $33.1M
- Mar 31, 2026: cash $56.6M, total assets $71.0M, total liabilities $58.2M, shareholders' equity $12.8M, long-term debt $33.1M
- Dec 31, 2025: cash $20.4M, total assets $35.3M, total liabilities $69.2M, shareholders' equity −$33.9M, long-term debt $33.0M
- Sep 30, 2025: cash $22.7M, total assets $36.5M, total liabilities $63.2M, shareholders' equity −$26.7M, long-term debt $32.8M
- Jun 30, 2025: cash $26.5M, total assets $41.3M, total liabilities $60.7M, shareholders' equity −$19.4M, long-term debt $32.3M
- Mar 31, 2025: cash $13.0M, total assets $28.6M, total liabilities $63.0M, shareholders' equity −$34.4M, long-term debt $31.7M
- Dec 31, 2024: cash $8.53M, total assets $24.0M, total liabilities $49.9M, shareholders' equity −$25.9M, long-term debt $22.1M
- Sep 30, 2024: cash $11.3M, total assets $27.5M, total liabilities $47.9M, shareholders' equity −$20.4M, long-term debt $21.7M
What is TLSI's revenue?
TriSalus Life Sciences Inc reported $45.1M of revenue over its last four quarters, through June 30, 2026.
Is TLSI profitable?
No. TriSalus Life Sciences Inc lost $28.2M over the last four quarters.
What is TLSI's EPS?
Diluted earnings per share over the last four quarters were −$1.31; −$0.16 in the latest quarter.